actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problemsactabiomedica-1803Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEКлинические предикторы кальцификации ксеноаортальных биопротезов клапанов сердцаClinical predictors of calcification of xenoaortic biological prosthesis of valvesКузьминаО. К.KuzminaO. K.Olga_shumilova@mail.ruНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийResearch Institute for Complex Issues of Cardiovascular Diseases201428092014051719Copyright © Кузьмина О.К., 20142014Кузьмина О.К.Kuzmina O.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/1803

Проведена ретроспективная оценка клинического статуса реципиентов биопротезов в митральной позиции: с гистологически подтвержденной кальцификацией - 1 группа, с нормальной морфологией и функцией протеза -11 группа. Полнота наблюдения составила 94,5 %, средние сроки наблюдения - 8,0 ± 4,4 года, объем наблюдения - 2792 пациенто-года. Для пациентов 1 группы характерны более тяжелое клиническое состояние и большая длительность искусственного кровообращения при выполнении первичных хирургических вмешательств. К числу факторов риска кальцификации биопротезов можно отнести степень декомпенсации сердечной недостаточности, продолжительность и травматичность хирургического вмешательства.

A retrospective analysis of clinical status of the recipients of biological prosthesis in mitral position was conducted: group 1 included patients with histologically confirmed calcification, group 11 included patients with normal morphology andfunctioning ofprosthesis. Follow-up depth was 94,5 %, average terms are 8,0 ± 4,4 years, follow-up scope is2792 patient-years. More severe clinical condition and prolonged cardiopulmonary bypass time while conducting primary surgical interventions are specific for the patients of the 1 group. The risk factors of prosthesis calcification are degree of cardiac failure decompensation, duration and traumatizing effect of surgical intervention.

кальцификациябиопротезыклинические предикторыcalcificationbioprosthesisclinical predictorsReferencesБарбараш Л.С., Барбараш Н.А., Журавлева И.Ю. Биопротезы клапанов сердца, проблемы и перспективы. - Кемерово, 1995. - 400 сБарбараш Л.С., Барбараш Н.А., Журавлева И.Ю. Биопротезы клапанов сердца, проблемы и перспективы. - Кемерово, 1995. - 400 сBonow R., Carabello B., Chatterjee K. et al. ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons // J. Am. Coll. Cardiol. - 2006. - Vol. 48 (3). - P. e1-148Bonow R., Carabello B., Chatterjee K. et al. ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons // J. Am. Coll. Cardiol. - 2006. - Vol. 48 (3). - P. e1-148Grabenwoger M., Sider J., Fitzal F. et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material // Ann. Thorac. Surg. - 1996. - Vol. 62 (3). - P. 772-777.Grabenwoger M., Sider J., Fitzal F. et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material // Ann. Thorac. Surg. - 1996. - Vol. 62 (3). - P. 772-777.Jamieson W.R., Cartier P.C., Allard M. et al. Surgical management of valvular heart disease // Can. J. Cardiol. - 2004. - Vol. 20, Suppl. E. - P. 7E-120E.Jamieson W.R., Cartier P.C., Allard M. et al. Surgical management of valvular heart disease // Can. J. Cardiol. - 2004. - Vol. 20, Suppl. E. - P. 7E-120E.Oakley R., Kleine P., Bach D.S. Choice of prosthetic heart valve in today’s practice // Circulation. - 2008. - Vol. 117 (2). - P. 253-256.Oakley R., Kleine P., Bach D.S. Choice of prosthetic heart valve in today’s practice // Circulation. - 2008. - Vol. 117 (2). - P. 253-256.Pibarot P., Dumesnil J. Prosthetic heart valves: selection of the optimal prosthesis and long-term management // Circulation. - 2009. - Vol. 119 (7). - P. 1034-1048.Pibarot P., Dumesnil J. Prosthetic heart valves: selection of the optimal prosthesis and long-term management // Circulation. - 2009. - Vol. 119 (7). - P. 1034-1048.Rahimtoola S.H. Choice of prosthetic heart valve for adult patients // J. Am. Coll. Cardiol. - 2003. - 41. - P. 893-904.Rahimtoola S.H. Choice of prosthetic heart valve for adult patients // J. Am. Coll. Cardiol. - 2003. - 41. - P. 893-904.Ruel M., Kulik A., Rubens F.D. et al. Late incidence and determinants of reoperation in patients with prosthetic heart valves // Eur. J. Cardiothorac. Surg. - 2004. - Vol. 25. - P. 364-370.Ruel M., Kulik A., Rubens F.D. et al. Late incidence and determinants of reoperation in patients with prosthetic heart valves // Eur. J. Cardiothorac. Surg. - 2004. - Vol. 25. - P. 364-370.Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention // Ann. Thorac. Surg. - 2005. - Vol. 79. - P. 1072-1080.Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention // Ann. Thorac. Surg. - 2005. - Vol. 79. - P. 1072-1080.Sophie E.P., Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification // Circ. Res. - 2011. - Vol. 108. - P. 1381-1391.Sophie E.P., Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification // Circ. Res. - 2011. - Vol. 108. - P. 1381-1391.Thiene G., Valente M. Anticalcification strategies to increase bioprosthetic valve durability // J. Heart Valve Dis. - 2011. - Vol. 20 (1). - P. 37-44.Thiene G., Valente M. Anticalcification strategies to increase bioprosthetic valve durability // J. Heart Valve Dis. - 2011. - Vol. 20 (1). - P. 37-44.Tillquist M., Maddox T. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement // Patient Prefer Adherence. - 2011. - Vol. 5. - P. 91-99.Tillquist M., Maddox T. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement // Patient Prefer Adherence. - 2011. - Vol. 5. - P. 91-99.Van Geldorp M., Jamieson E., Kappetein A.P. et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk // J. Thorac. Cardiovasc. Surg. - 2009. - Vol. 137. - P. 881-886.Van Geldorp M., Jamieson E., Kappetein A.P. et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk // J. Thorac. Cardiovasc. Surg. - 2009. - Vol. 137. - P. 881-886.Vesey J.M., Otto C.M. Complication of prosthetic heart valves // Curr. Cardiol. Rep. - 2004. - Vol. 6. - P. 106-111.Vesey J.M., Otto C.M. Complication of prosthetic heart valves // Curr. Cardiol. Rep. - 2004. - Vol. 6. - P. 106-111.

The authors declare that there are no conflicts of interest present.